2007 Annual Meeting | Unusual Diagnostic and Management Problems in Neuromuscular Disease

Date Wednesday 05/02/07

Time 07:00 PM - 10:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Case Studies Program

Director(s) Carlayne E. Jackson, MD, FAAN

Topic(s)

Learning Objectives Participants should become more familiar with the differential diagnosis, evaluation, management, and treatment of both common and unusual neuromuscular disorders.

CME Available No CME available

Core Competencies Medical Knowledge, Practice-based Learning and Improvement

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
06:45 PM - 10:00 PM		Reception
07:00 PM - 10:00 PM		Unusual Diagnostic and Management Problems in Neuromuscular Disease Carlayne E. Jackson, MD, FAAN, John T. Kissel, MD, FAAN, Jeffrey Rosenfeld, MD, PhD, FAAN

Faculty Disclosures
Carlayne E. Jackson, MD, FAAN	Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital.
John T. Kissel, MD, FAAN	Dr. Kissel has nothing to disclose.
Jeffrey Rosenfeld, MD, PhD, FAAN	Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ML Biosolutions. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for MT Pharma America. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amylyx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for NeuroSense. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Catalyst. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexion. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Anelixis. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroSense. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for MT Pharma America. Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Strongbridge Pharma. Dr. Rosenfeld has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx. The institution of Dr. Rosenfeld has received research support from MT Pharma. The institution of Dr. Rosenfeld has received research support from Alexion. The institution of Dr. Rosenfeld has received research support from Healey ALS Trial Center Mass General.

��ɫ��

��ɫ��